Drug resistant falciparum malaria: clinical consequences and strategies for prevention

被引:51
作者
Price, RN [1 ]
Nosten, F
机构
[1] John Radcliffe Hosp, Nuffield Dept Clin Med, Ctr Trop Med, Oxford OX3 9DU, England
[2] Shoklo Malaria Res Unit, Mae Sot, Thailand
[3] Mahidol Univ, Fac Trop Med, Bangkok, Thailand
关键词
D O I
10.1054/drup.2001.0195
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The rising prevalence of multidrug resistant falciparum malaria is occurring at an alarming rate and has serious implications for the health of many of the worlds poorest countries. The dangers of not changing treatment practices immediately are huge and irreversible, threatening to both exacerbate the scale and scope of the malaria pandemic, and deprive policymakers of future options against the disease. If a health care disaster is to be avoided then massive and long term funding is urgently required. Funds need to be applied in a cohesive manner, accountable to funding bodies and tailored to the specifics of each endemic region. The key elements of such an approach should be improving early diagnosis and treatment of infection and the deployment of combination regimens containing an artemisinin derivative. These short term measures will need to be accompanied by a longer term strategy to encourage antimalarial drug research and development. (C) 2001 Harcourt Publishers Ltd.
引用
收藏
页码:187 / 196
页数:10
相关论文
共 61 条
[1]  
[Anonymous], WORLD HLTH REP
[2]  
Bloland PB, 1999, ANN TROP MED PARASIT, V93, P5, DOI 10.1080/00034989958753
[3]  
Bloland PB, 1998, TROP MED INT HEALTH, V3, P543
[4]   SEQUENCE VARIATION OF THE HYDROXYMETHYLDIHYDROPTERIN PYROPHOSPHOKINASE - DIHYDROPTEROATE SYNTHASE GENE IN-LINE SO THE HUMAN MALARIA PARASITE, PLASMODIUM-FALCIPARUM, WITH DIFFERING RESISTANCE TO SULFADOXINE [J].
BROOKS, DR ;
WANG, P ;
READ, M ;
WATKINS, WM ;
SIMS, PFG ;
HYDE, JE .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1994, 224 (02) :397-405
[5]  
CHAWIRA AN, 1987, J TROP MED HYG, V90, P1
[6]   THE EFFECT OF COMBINATIONS OF QINGHAOSU (ARTEMISININ) WITH STANDARD ANTIMALARIAL-DRUGS IN THE SUPPRESSIVE TREATMENT OF MALARIA IN MICE [J].
CHAWIRA, AN ;
WARHURST, DC ;
ROBINSON, BL ;
PETERS, W .
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 1987, 81 (04) :554-558
[7]  
Djimdé A, 2001, NEW ENGL J MED, V344, P257, DOI 10.1056/NEJM200101253440403
[8]   Estimates of the infectious reservoir of Plasmodium falciparum malaria in The Gambia and in Tanzania [J].
Drakeley, CJ ;
Akim, NIJ ;
Sauerwein, RW ;
Greenwood, BM ;
Targett, GAT .
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 2000, 94 (05) :472-476
[9]   Randomized controlled trial of artesunate plus tetracycline versus standard treatment (quinine plus tetracycline) for uncomplicated Plasmodium falciparum malaria in Brazil [J].
Duarte, EC ;
Fontes, CJF ;
Gyorkos, TW ;
Abrahamowicz, M .
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 1996, 54 (02) :197-202
[10]   Increased sensitivity to the antimalarials mefloquine and artemisinin is conferred by mutations in the pfmdr1 gene of Plasmodium falciparum [J].
Duraisingh, MT ;
Roper, C ;
Walliker, D ;
Warhurst, DC .
MOLECULAR MICROBIOLOGY, 2000, 36 (04) :955-961